FDA Drug Approval: ProPublica Investigation
- Potential gaps in the Food adn Drug governance's (FDA) oversight of foreign drug manufacturers are raising concerns about the safety of some generic drugs available in the United...
- The analysis counted all drugs exempted from each banned factory.
- More than 8,000 reports about drugs excused from factorywide import bans were identified both before and after the bans were implemented.
The FDA’s oversight of generic drugs faces scrutiny as a new analysis reveals potential safety concerns. The examination suggests the FDA allowed the import of drugs from factories with documented safety issues. Over 8,000 adverse event reports are linked to these exempted drugs, sparking serious questions about drug safety. Companies with troubled regulatory histories also received approvals, raising further concerns. News Directory 3 reports on the FDA’s role and the evolving landscape of foreign drug manufacturing. Discover what’s next as additional records may soon shed more light on the agency’s actions and the potential risks involved.
FDA Drug Oversight Raises Safety Concerns About Generic Drugs
Potential gaps in the Food adn Drug governance’s (FDA) oversight of foreign drug manufacturers are raising concerns about the safety of some generic drugs available in the United States. an analysis suggests that the FDA has,at times,allowed drugs from factories with significant safety issues to continue being imported.
The analysis counted all drugs exempted from each banned factory. in some instances, the same drug was exempted from multiple factories and added to each factory’s total.Different formulations of the same drug, such as tablets, capsules, or injectables, were counted as distinct drugs.
More than 8,000 reports about drugs excused from factorywide import bans were identified both before and after the bans were implemented. The analysis included reports from 2010 to early 2025.
The FDA cautions that data in these reports is not verified and there may be no “causal relationship” between the drug and the adverse event. The analysis was limited to cases that listed only one primary suspect drug.
The FDA’s Orange Book, a register of drugs considered safe and effective, was used to examine the agency’s role in the growth of foreign drugmakers. The analysis showed that companies with troubled regulatory histories received numerous approvals to introduce generic drugs in the United States, and some later received exemptions from import bans.
journalists have uncovered problems with generic drugs for years. Katherine Eban’s bestselling 2019 book, “Bottle of Lies,” exposed how Indian drugmakers failed to follow basic quality and safety standards and often knowingly sent shoddy drugs abroad. In 2023, a Bloomberg inquiry revealed, among othre things, how poisoned cough syrup made in India spread around the world. And the autonomous watchdog The People’s Pharmacy has raised repeated concerns about the quality of some generic drugs.
What’s next
Ongoing legal action may compel the FDA to release additional records related to drug safety, potentially shedding more light on the agency’s oversight of foreign drug manufacturers and the potential risks to consumers.